Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

Abstract Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had...

Full description

Bibliographic Details
Main Authors: Ahmed Abbasi, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, Richard Elkind, Karen Fehn, Alyssa de Castro, Yanhua Wang, Olga Derman, Randin Nelson, Joan Uehlinger, Kira Gritsman, R. Alejandro Sica, Noah Kornblum, Ioannis Mantzaris, Aditi Shastri, Murali Janakiram, Mendel Goldfinger, Amit Verma, Ira Braunschweig, Lizamarie Bachier-Rodriguez
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Journal of Hematology & Oncology
Subjects:
CD19 CAR-T
HIV and CD-19 CAR-T
CNS and CD-19 CAR-T
Axi-cel
Hepatitis B and CD-19 CAR-T
Online Access:https://doi.org/10.1186/s13045-019-0838-y

Internet

https://doi.org/10.1186/s13045-019-0838-y

Similar Items